Assignee
NEUPHARMA INC
US·34 granted patents·12 pending applications·164 citations·filing 2012–2023
Top patents by PatentIndex Score
46 records- 0198US11304957B2Substituted quinazolines for inhibiting kinase activityNEUPHARMA INC·Filed 2020·Granted Apr 19, 2022·4 cites·6 claims
- 0297US11865120B2Substituted quinazolines for inhibiting kinase activityNEUPHARMA INC·Filed 2022·Granted Jan 9, 2024·2 cites·14 claims
- 0397US10172868B2Substituted quinazolines for inhibiting kinase activityNEUPHARMA INC·Filed 2017·Granted Jan 8, 2019·10 cites·25 claims
- 0497US9849139B2Substituted quinazolines for inhibiting kinase activityNEUPHARMA INC·Filed 2016·Granted Dec 26, 2017·12 cites·40 claims
- 0597US9550770B2Substituted quinazolines for inhibiting kinase activityNEUPHARMA INC·Filed 2014·Granted Jan 24, 2017·15 cites·28 claims
- 0695US10653701B2Substituted quinazolines for inhibiting kinase activityNEUPHARMA INC·Filed 2018·Granted May 19, 2020·7 cites·22 claims
- 0795US9572808B2Benzenesulfonamide derivatives of quinoxaline, pharmaceutical compositions thereof, and their use in methods for treating cancerNEUPHARMA INC·Filed 2015·Granted Feb 21, 2017·13 cites·11 claims
- 0895US9249111B2Substituted quinoxalines as B-RAF kinase inhibitorsNEUPHARMA INC·Filed 2012·Granted Feb 2, 2016·13 cites·35 claims
- 0993US9249110B2Substituted quinoxalines as B-raf kinase inhibitorsNEUPHARMA INC·Filed 2012·Granted Feb 2, 2016·13 cites·40 claims
- 1092US10947201B2Certain chemical entities, compositions, and methodsNEUPHARMA INC·Filed 2016·Granted Mar 16, 2021·6 cites·15 claims
- 1190US12403145B2Substituted quinazolines for inhibiting kinase activityNEUPHARMA INC·Filed 2023·Granted Sep 2, 2025·0 cites·20 claims
- 1290US10544106B2Certain chemical entities, compositions, and methodsNEUPHARMA INC·Filed 2017·Granted Jan 28, 2020·7 cites·27 claims
- 1390US10065986B2Certain chemical entities, compositions, and methodsNEUPHARMA INC·Filed 2016·Granted Sep 4, 2018·6 cites·14 claims
- 1489US9688635B2Certain chemical entities, compositions, and methodsNEUPHARMA INC·Filed 2013·Granted Jun 27, 2017·10 cites·23 claims
- 1589US9676813B2Certain steroids and methods for using the same in the treatment of cancerNEUPHARMA INC·Filed 2013·Granted Jun 13, 2017·9 cites·20 claims
- 1688US9670180B2Certain chemical entities, compositions, and methodsNEUPHARMA INC·Filed 2013·Granted Jun 6, 2017·9 cites·53 claims
- 1787US11208388B2Certain chemical entities, compositions, and methodsNEUPHARMA INC·Filed 2019·Granted Dec 28, 2021·2 cites·17 claims
- 1886US10065932B2Certain chemical entities, compositions, and methodsNEUPHARMA INC·Filed 2017·Granted Sep 4, 2018·3 cites·22 claims
- 1986US9908866B2Certain chemical entities, compositions, and methodsNEUPHARMA INC·Filed 2017·Granted Mar 6, 2018·5 cites·23 claims
- 2086US9822081B2Certain chemical entities, compositions, and methodsNEUPHARMA INC·Filed 2016·Granted Nov 21, 2017·3 cites·20 claims
- 2184US9725421B2Substituted quinoxalines as B-raf kinase inhibitorsNEUPHARMA INC·Filed 2013·Granted Aug 8, 2017·6 cites·24 claims
- 2282US10137125B2Benzenesulfonamide derivatives of quinoxaline, pharmaceutical compositions thereof, and their use in methods for treating cancerNEUPHARMA INC·Filed 2017·Granted Nov 27, 2018·2 cites·26 claims
- 2382US10047059B2Substituted quinoxalines for inhibiting kinase activityNEUPHARMA INC·Filed 2017·Granted Aug 14, 2018·3 cites·20 claims
- 2481US10344048B2Certain chemical entities, compositions, and methodsNEUPHARMA INC·Filed 2016·Granted Jul 9, 2019·2 cites·38 claims
- 2579US10561652B2Benzenesulfonamide derivatives of quinoxaline, pharmaceutical compositions thereof, and their use in methods for treating cancerNEUPHARMA INC·Filed 2019·Granted Feb 18, 2020·1 cites·20 claims
- 2679US2022251049A1Certain chemical entities, compositions, and methodsNEUPHARMA INC·Filed 2021·Application pending·0 cites
- 2778US11325940B2Certain chemical entities, compositions, and methodsNEUPHARMA INC·Filed 2019·Granted May 10, 2022·0 cites·20 claims
- 2878US2021113593A1Certain chemical entities, compositions, and methodsNEUPHARMA INC·Filed 2020·Application pending·0 cites
- 2976US10766920B2Certain chemical entities, compositions, and methodsNEUPHARMA INC·Filed 2019·Granted Sep 8, 2020·0 cites·29 claims
- 3076US2024115585A1Methods of treating cancerNEUPHARMA INC·Filed 2023·Application pending·0 cites
- 3175US2020390763A1Benzenesulfonamide derivatives of quinoxaline, pharmaceutical compositions thereof, and their use in methods for treating cancerNEUPHARMA INC·Filed 2020·Application pending·0 cites
- 3274US10457641B2Certain chemical entities, compositions, and methodsNEUPHARMA INC·Filed 2017·Granted Oct 29, 2019·1 cites·22 claims
- 3373US12018002B2Certain chemical entities, compositions, and methodsNEUPHARMA INC·Filed 2021·Granted Jun 25, 2024·0 cites·15 claims
- 3472US2021040048A1Certain chemical entities, compositions, and methodsNEUPHARMA INC·Filed 2020·Application pending·0 cites
- 3571US10759766B2Certain chemical entities, compositions, and methodsNEUPHARMA INC·Filed 2019·Granted Sep 1, 2020·0 cites·20 claims
- 3667US2020354398A1Certain chemical entities, compositions, and methodsNEUPHARMA INC·Filed 2020·Application pending·0 cites
- 3766US11465975B2Certain chemical entities, compositions, and methodsNEUPHARMA INC·Filed 2019·Granted Oct 11, 2022·0 cites·30 claims
- 3865US2024092825A1Certain chemical entities, compositions, and methodsNEUPHARMA INC·Filed 2023·Application pending·0 cites
- 3963US2020330486A1Methods of treating cancerNEUPHARMA INC·Filed 2018·Application pending·0 cites
- 4063US2021163423A1Certain chemical entities, compositions, and methodsNEUPHARMA INC·Filed 2021·Application pending·0 cites
- 4162US10487108B2Certain steroids and methods for using the same in the treatment of cancerNEUPHARMA INC·Filed 2017·Granted Nov 26, 2019·0 cites·42 claims
- 4260US2024207256A1Certain chemical entities, compositions, and methodsNEUPHARMA INC·Filed 2022·Application pending·0 cites
- 4359US2024116880A1Certain chemical entities, compositions, and methodsNEUPHARMA INC·Filed 2021·Application pending·0 cites
- 4456US10590106B2Certain chemical entities, compositions, and methodsNEUPHARMA INC·Filed 2018·Granted Mar 17, 2020·0 cites·21 claims
- 4556US9707202B2Certain chemical entities, compositions, and methodsNEUPHARMA INC·Filed 2016·Granted Jul 18, 2017·0 cites·18 claims
- 4655US2017050938A1Substituted quinoxalines as b-raf kinase inhibitorsNEUPHARMA INC·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when NEUPHARMA INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →